linjc16/ctgov huggingface dataset:
Functional Residual Capacity Measured by Capnography in Ventilated Patients

Study Overview
=================
Brief Summary
-----------------
Changes in body position during anesthesia can alter functional residual capacity and gas exchange. The monitoring of such changes in functional residual capacity is difficult at the bedside. The present study was designed to determine if volumetric capnography can detect changes in the functional residual capacity during surgery.

Detailed Description
-----------------
This is a prospective and observational study designed to test the reliability of the capnodynamic equation to determine changes in functional residual capacity measured during anesthesia. The investigators will studied 40 mechanically ventilated patients undergoing general anesthesia. Functional residual capacity will be continuously measured in a non invasive way using expired carbon dioxide. Changes in functional residual capacity with standard modification in body positioning (Trendelenburg or anti-Trendelenburg position) and ventilatory settings wiil be tested.

Official Title
-----------------
Effect of Positive End-expiratory Pressure on Functional Residual Capacity Measured by Volumetric Capnography in Mechanically Ventilated Patients

Conditions
-----------------
Respiratory Physiological Phenomena

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written Inform Consent Programmed surgery Laparoscopic surgery Supine position Exclusion Criteria: Emergency surgery Chronic respiratory disease Active smoking

Ages Eligible for Study
-----------------
Minimum Age: 30 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients undergoing surgeries<br>Patients ASA 1-3, undergoing different types of general anesthesia that need postural changes like Trendelenburg and anti-Trendelenburg positioning. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Functional Residual Capacity Measured by Capnography in Ventilated Patients | Measurement of functional residual capacity with capnography with body positioning changes. | 6 hours |
Genetic Studies in Familial Dementia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to identify genetic factors that contribute to or cause dementia (loss of memory) and related disorders across all ages and ethnic groups. This includes a number of neurological diseases such as early and late-onset Alzheimer disease, mild cognitive impairment, and other dementias.

Official Title
-----------------
Genetic Studies in Familial Dementia

Conditions
-----------------
Dementia, Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 years and older Patients diagnosed with dementia, their family members and unrelated healthy controls without dementia. Exclusion Criteria: 1. Individuals with competing diagnosis such as: Amyotrophic lateral sclerosis, Frontotemporal lobar degeneration, Multiple system atrophy, Corticobasal degeneration, Progressive Supranuclear Palsy, Huntington's disease, traumatic brain injury, drug or alcohol abuse, or schizophrenia, etc. (unless family members of a dementia affected individual).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cognitive Control<br>Participants in this group are cognitively intact. | |
| Mild Cognitive Impairment<br>Participants in this group have mild cognitive impairment. | |
| Dementia Group<br>Participants in this group have dementia. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between genetic factors and Alzheimer disease, dementia, and related phenotypes. | Genetic factors will be measured through genome-wide genotyping arrays and/or whole-genome sequencing, and then correlated with Alzheimer disease and related phenotypes, such as cognitive impairment, functional impairment, and relevant biomarkers. . | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Memory loss
Comparing Bubble and Ventilator Nasal CPAP in Preterm Infants

Study Overview
=================
Brief Summary
-----------------
There are various methods to generate the pressure needed for Nasal CPAP. Some neonatal intensive care units (NICU) use an underwater bubbling system and others use a ventilator to generate the pressure. There is no right or wrong way to generate the pressure and both methods are approved and accepted. The aim of this study is to compare the two systems of Nasal CPAP by placing the baby on each for a defined time period and reviewing the infant's vital signs. The investigators expect that the pressure generated by bubble CPAP will be better and lead to improved vital signs.

Detailed Description
-----------------
There are various methods to generate the pressure needed for Nasal CPAP. Some neonatal intensive care units (NICU) use an underwater bubbling system and others use a ventilator to generate the pressure. There is no right or wrong way to generate the pressure and both methods are approved and accepted. The aim of this study is to compare the two systems of Nasal CPAP by placing the baby on each for a defined time period and reviewing the infant's vital signs. The investigators expect that the pressure generated by bubble CPAP will be better and lead to improved vital signs.

Official Title
-----------------
Comparing the Effects of Bubble Nasal CPAP Versus Ventilator Nasal CPAP in Preterm Infants

Conditions
-----------------
Respiratory Distress Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Neonates between 26-32 weeks gestational age who have been on Nasal CPAP for at least 48hrs on fraction of inspired oxygen (FiO2) of < or = 0.3. Parental consent will be obtained prior to enrollment. Exclusion Criteria: Infants with severe congenital anomalies, such as airway or chest wall deformities, pulmonary hypoplasia, congenital heart disease, neurologic abnormalities including severe intraventricular hemorrhage (IVH) and need for surgery eg. for necrotizing enterocolitis will be excluded from the study. Any infants with genetic/chromosomal abnormalities will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 2 Days
Maximum Age: 3 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Premature infant<br>Each premature infant will be on bubble nasal CPAP for 2 hours and on ventilator nasal CPAP for 2 hours | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physiologic parameters | heart rate, respiratory rate, oxygen saturation | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Physiologic parameters | cerebral oxygen tissue extraction | 2 hours |
Modification of Allergic Immunologic Response by Leukotriene Antagonists - Ancillary to ACRN IMPACT

Study Overview
=================
Brief Summary
-----------------
To examine the cellular and molecular mechanisms of corticosteroid and leukotriene receptor antagonists, focusing on their effects on T lymphocytes during both chronic (18 months) and acute therapy.

Detailed Description
-----------------
BACKGROUND: Asthma is a chronic inflammatory disease. T lymphocytes are essential for initiating and maintaining the asthmatic inflammatory immune response. Corticosteroid treatment targets several inflammatory responses, including T lymphocytemediated responses. In addition, leukotriene receptor antagonists (LTRA) may influence T cell activation. To investigate the effects of these two controller agents in the treatment of asthma on airway function is the goal of the IMPACT clinical trial in mild chronic adult asthmatics. The Improving Asthma Control Trial (IMPACT) is one of the trials within the NHLBI-supported Asthma Clinical Research Network (ACRN). IMPACT is a double-blind, randomized, parallel group design clinical trial to determine the best long-term strategy for treating adults with mild asthma who experience symptoms more than occasionally. The trial will test whether these patients should be taking anti-inflammatory medications on a daily basis and whether a newer class of medications provides the same benefit as older drugs. In the IMPACT study, 234 adults with mild asthma who have more than occasional symptoms will be enrolled in six clinical research centers. Following an initial evaluation, patients will be randomized to receive either a twice daily inhaled corticosteroid, a twice daily anti-leukotriene, or a placebo. All patients will receive treatment for symptoms if and when they occur. The results should demonstrate whether medication is required on a daily basis by these patients, and if so, whether inhaled corticosteroids and leukotriene modifiers are equally effective. Recruitment began in May, 2000. The trial is expected to be completed in 2003. The study is in response to an initiative Ancillary Studies in Heart, Lung, and Blood Disease Trials released by the National Heart, Lung, and Blood Institute in June 2000. DESIGN NARRATIVE: A total of 39 patients, 13 in each arm, will be randomized to inhaled steroid, leukotriene receptor antagonist or placebo and followed for 18 months for changes in T-cell costimulatory pathways. The study completion date listed in this record was obtained from the End Date entered in the Protocol Registration and Results System (PRS) record.

Conditions
-----------------
Asthma, Lung Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
No eligibility criteria

Ages Eligible for Study
-----------------
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
BIOFLOW-INDIA Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in Single de Novo Coronary Artery Lesions

Study Overview
=================
Brief Summary
-----------------
The objective of this clinical investigation is to assess the safety and clinical performance of the Orsiro Limus Eluting Stent System in Indian subjects with single de-novo coronary artery lesions.

Official Title
-----------------
BIOTRONIK-Safety and Clinical PerFormance of the Drug Eluting ORSIRO Stent in the Treatment of Patients With Single de Novo Coronary Artery Lesions in an Indian Population

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: Percutaneous Coronary Intervention Biotronik Orsiro DES


Participation Criteria
=================
Eligibility Criteria
-----------------
Main Inclusion Criteria: Subject has provided a written informed consent Single de novo lesion with ≥ 50% and <100% stenosis in up to 2 coronary arteries The target lesion length is ≤ 26 mm The target reference vessel diameter is ≥ 2.0 mm and ≤ 4.0 mm Main Exclusion Criteria: Evidence of myocardial infarction within 72 hours prior to index procedure Unprotected left main coronary artery disease (stenosis >50%) Three-vessel coronary artery disease at time of procedure Thrombus in target vessel Target lesion involves a side branch > 2.0 mm in diameter Heavily calcified lesion Target lesion is located in or supplied by an arterial or venous bypass graft

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Biotronik Orsiro DES<br> | Device: Percutaneous Coronary Intervention Biotronik Orsiro DES<br>* Stenting<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| In-Stent Late Lumen Loss |  | 9 months post index procedure |
Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae

Study Overview
=================
Brief Summary
-----------------
This is a study of the genetics of malaria transmission by the mosquito vector in Africa, Anopheles gambiae. The study focuses on the mosquito vector, not the human subjects infected with malaria. DNA extracted from infected mosquitoes will be analyzed genetically by microsatellite and single-nucleotide polymorphisms (SNPs) to identify mosquito genes that control mosquito resistance to malaria parasites.

Detailed Description
-----------------
A standard diagnostic blood smear from a drop of blood will be carried out on 20 study subjects once per month. One malaria-positive subject from among the 20 will be asked to donate 5cc of blood, also no more frequently than once per month. The blood will be placed in a water-jacketed heated membrane feeding device that will be positioned on top of a cage of mosquitoes. The mosquitoes are attracted to the warmth and drink the blood through the artificial skin-like membrane. The goal of the research is to study the infected mosquitoes. No studies will be carried out on the human subjects. The point of human subjects involvement is to obtain the naturally malaria-infected blood for feeding of mosquitoes. After blood feeding, the mosquitoes are held in an environmental chamber for one week, at which time they are dissected to count numbers of malaria parasites developing on the mosquito stomach wall. This number constitutes the quantitative phenotype, and we extract genomic DNA from the carcass for genetic marker typing, which constitutes the genotype. Genetic linkage analysis identifies markers near genes that control parasite number, thus resistance or susceptibility to parasite infection.

Official Title
-----------------
Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae

Conditions
-----------------
Malaria

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 5-10 years old, and general good health Exclusion Criteria: Outside age group Specific diagnosable health problems General poor health

Ages Eligible for Study
-----------------
Minimum Age: 5 Years
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| mosquito infection | Protocol involves non-invasive blood draw from participant screened by finger-prick for infection with malaria. Drawn blood (0.5cc) is placed in artificial membrane feeder for feeding of mosquitoes. Primary outcome is infection of mosquitoes, detectable one week after blood feeding. | one week |
Assessment of Cancer Concerns at the End of Treatment (ACE)

Study Overview
=================
Brief Summary
-----------------
This study will describe patient-reported symptom burden and concerns, quality of life (QOL), and health behaviors of breast cancer(BC) survivors who have completed initial treatments (e.g., surgery, chemotherapy, and/or radiotherapy), assess the feasibility of using a web-based platform to collect patient-reported outcome (PRO) data, and evaluate provider satisfaction following delivery of an electronic health record (HER)/EPIC summary of these PROs. Secondary aims will estimate differences in referral to available services between those providers exposed to the PRO summary and historical controls. BC survivors who have completed initial treatment and present within the first year following treatment for an end of treatment (EOT)/survivorship focused visit will be the focus of this study.

Official Title
-----------------
Assessment of Cancer Concerns at the End of Treatment (ACE)

Conditions
-----------------
Breast Cancer(BC) Survivors

Intervention / Treatment
-----------------
* Behavioral: Questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with invasive, non-metastatic BC (Stage I, II, or III) without hematogenous or distant metastases Have completed initial treatment (chemotherapy, radiotherapy, and/or surgery). May still be receiving hormonal or targeted therapy (e.g., tamoxifen, aromatase inhibitors). Within 1 year of completing primary treatment Scheduled for an EOT visit Age 18 years or older Can understand written English Have internet access and a working email address Exclusion Criteria: Diagnosed with non-invasive (Stage 0/DCIS) or metastatic (Stage IV) cancer or hematogenous or distant metastatic disease No working email address -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Questionnaire|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Completion of Questionnaire |  | 2 years |
Is it Necessary to Drain in Contact With the Prostheses During a Cure of a Ventricle With Retromuscular Prosthesis?

Study Overview
=================
Brief Summary
-----------------
Is there an indication for drainage in contact with a prosthesis placed in a retromuscular position, during a cure for abdominal wall ventration in adults? This procedure is very frequent in digestive surgery and can be associated with serious complications, notably prosthesis infection.

Official Title
-----------------
Is it Necessary to Drain in Contact With the Prostheses During a Cure of a Ventricle With Retromuscular Prosthesis?

Conditions
-----------------
Eventration of the Abdominal Wall

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Adult patient (≥18 years old) Patient operated on at HUS between 01/01/2018 and 12/31/2020 Patient who has undergone surgical cure of anterior or lateral abdominal wall eventration of any width with placement during the procedure of a prosthetic mesh in a prefascial retromuscular position. Patient not objecting to the reuse of their data for scientific research purposes. Exclusion criteria: Patient who has expressed opposition to the reuse of his or her data for scientific research purposes. Particular clinical forms of the disease: absence of previous surgical intervention (and thus absence of ventration: umbilical hernia, diastasis) Absence of prosthesis during the operation or prosthesis placed in intraperitoneal position

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| infection after drainage in contact with a retromuscular prosthesis |  | 1 day after surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Eventration of the abdominal wall, Hernia, Drainage, Retromuscular position, Digestive surgery
Intracardiac T-wave Alternans and Ischemia

Study Overview
=================
Brief Summary
-----------------
T-wave alternans is a test that looks at microvolt changes in the T-wave on a beat to beat basis. The presence or absence of such changes has been shown to predict or exclude future arrhythmic events. The mechanism of T-wave alternans is unclear, but may relate to calcium metabolism in the heart, and may be affected by conditions such as ischemia or heart failure. The purpose of this study is to determine whether T-wave alternans, as measured through the lead of an implantable defibrillator, is produced by acute ischemia induced by occlusion during percutaneous coronary interventions.

Official Title
-----------------
Intracardiac T-wave Alternans and Ischemia During Percutaneous Coronary Interventions

Conditions
-----------------
Ischemia

Intervention / Treatment
-----------------
* Procedure: Percutaneous coronary intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient with CAD undergoing PCI with appropriate Medtronic implantable defibrillator. Exclusion Criteria: non-elective procedure non-qualifying defibrillator type.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medtronic defibrillator<br>Patients undergoing a percutaneous coronary intervention (PCI) with an implanted Medtronic defibrillator with the capability of telemetry of the intracardiac signal. | Procedure: Percutaneous coronary intervention<br>* PCI previously electively scheduled.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Subjects With Positive T Wave Studies During a Coronary Intervention | Positive T wave alternans is determined by a proprietary program using ECG recordings during a stress test. The result is reported as positive, negative, or indeterminate. | During the coronary intervention, upto 2 hours |